JP6983653B2 - ワクチン - Google Patents

ワクチン Download PDF

Info

Publication number
JP6983653B2
JP6983653B2 JP2017511582A JP2017511582A JP6983653B2 JP 6983653 B2 JP6983653 B2 JP 6983653B2 JP 2017511582 A JP2017511582 A JP 2017511582A JP 2017511582 A JP2017511582 A JP 2017511582A JP 6983653 B2 JP6983653 B2 JP 6983653B2
Authority
JP
Japan
Prior art keywords
denv
ediii
hbsag
dengue virus
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017511582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526366A (ja
JP2017526366A5 (enExample
Inventor
カンナ，ナビン
ラーマサーミ，ヴィスワナータン
Original Assignee
インターナショナル センター フォー ジェネティック エンジニアリング アンド バイオテクノロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターナショナル センター フォー ジェネティック エンジニアリング アンド バイオテクノロジー filed Critical インターナショナル センター フォー ジェネティック エンジニアリング アンド バイオテクノロジー
Publication of JP2017526366A publication Critical patent/JP2017526366A/ja
Publication of JP2017526366A5 publication Critical patent/JP2017526366A5/ja
Priority to JP2020096790A priority Critical patent/JP6985458B2/ja
Priority to JP2021191104A priority patent/JP7333373B2/ja
Application granted granted Critical
Publication of JP6983653B2 publication Critical patent/JP6983653B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Cartons (AREA)
  • Packaging Of Annular Or Rod-Shaped Articles, Wearing Apparel, Cassettes, Or The Like (AREA)
JP2017511582A 2014-09-01 2015-08-21 ワクチン Active JP6983653B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020096790A JP6985458B2 (ja) 2014-09-01 2020-06-03 ワクチン
JP2021191104A JP7333373B2 (ja) 2014-09-01 2021-11-25 ワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2478/DEL/2014 2014-09-01
IN2478DE2014 2014-09-01
PCT/IB2015/056352 WO2016034974A1 (en) 2014-09-01 2015-08-21 Vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020096790A Division JP6985458B2 (ja) 2014-09-01 2020-06-03 ワクチン

Publications (3)

Publication Number Publication Date
JP2017526366A JP2017526366A (ja) 2017-09-14
JP2017526366A5 JP2017526366A5 (enExample) 2018-09-27
JP6983653B2 true JP6983653B2 (ja) 2021-12-17

Family

ID=55439184

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017511582A Active JP6983653B2 (ja) 2014-09-01 2015-08-21 ワクチン
JP2020096790A Active JP6985458B2 (ja) 2014-09-01 2020-06-03 ワクチン
JP2021191104A Active JP7333373B2 (ja) 2014-09-01 2021-11-25 ワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020096790A Active JP6985458B2 (ja) 2014-09-01 2020-06-03 ワクチン
JP2021191104A Active JP7333373B2 (ja) 2014-09-01 2021-11-25 ワクチン

Country Status (18)

Country Link
US (3) US10189877B2 (enExample)
EP (2) EP3188755B1 (enExample)
JP (3) JP6983653B2 (enExample)
CN (1) CN107074968B (enExample)
CA (1) CA2959280C (enExample)
CY (1) CY1123664T1 (enExample)
ES (1) ES2821480T3 (enExample)
HR (1) HRP20201523T1 (enExample)
HU (1) HUE053284T2 (enExample)
LT (1) LT3188755T (enExample)
MX (2) MX385222B (enExample)
MY (1) MY201688A (enExample)
PL (1) PL3188755T3 (enExample)
PT (1) PT3188755T (enExample)
RS (1) RS61000B1 (enExample)
SI (1) SI3188755T1 (enExample)
SM (1) SMT202000589T1 (enExample)
WO (1) WO2016034974A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2821480T3 (es) * 2014-09-01 2021-04-26 Int Centre For Genetic Engineering And Biotechnology Vacuna
EP3621645A4 (en) * 2017-05-10 2021-01-27 University of Massachusetts BIVALENT VACCINES AGAINST DENGUE / HEPATITIS B

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
JP3954643B2 (ja) * 1991-11-16 2007-08-08 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム マラリア原虫由来のＣＳおよびＨＢｓＡＧ間のハイブリッド蛋白質
FR2741077B1 (fr) * 1995-11-14 1998-01-23 Pasteur Institut Vaccin polyvalent anti-dengue
WO2007034507A2 (en) * 2005-09-20 2007-03-29 International Centre For Genetic Engineering And Biotechnology Tetravalent dengue specific domain iii based chimeric recombinant protein
WO2008152652A2 (en) * 2007-06-12 2008-12-18 International Centre For Genetic Engineering And Biotechnology A dengue envelope domain iii-based tetravalent protein vaccine
WO2010043977A2 (en) * 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
CN101962411B (zh) * 2009-07-24 2012-09-05 中国疾病预防控制中心病毒病预防控制所 登革病毒血清学早期诊断试剂
CN102906266A (zh) * 2010-05-21 2013-01-30 高等教育联邦系统-匹兹堡大学 登革病毒通用序列及其使用方法
CN103193870B (zh) * 2013-04-22 2014-10-22 中国人民解放军第三军医大学 一种登革病毒简并疫苗及其应用
ES2821480T3 (es) * 2014-09-01 2021-04-26 Int Centre For Genetic Engineering And Biotechnology Vacuna

Also Published As

Publication number Publication date
SI3188755T1 (sl) 2021-03-31
EP3685852A1 (en) 2020-07-29
CY1123664T1 (el) 2022-03-24
HRP20201523T1 (hr) 2021-03-05
WO2016034974A1 (en) 2016-03-10
JP2020162611A (ja) 2020-10-08
RS61000B1 (sr) 2020-11-30
US10815280B2 (en) 2020-10-27
US11945842B2 (en) 2024-04-02
CA2959280A1 (en) 2016-03-10
JP7333373B2 (ja) 2023-08-24
US20210122787A1 (en) 2021-04-29
ES2821480T3 (es) 2021-04-26
MX385222B (es) 2025-03-14
CA2959280C (en) 2023-09-26
JP6985458B2 (ja) 2021-12-22
US20190194261A1 (en) 2019-06-27
BR112017004008A2 (pt) 2018-01-23
CN107074968B (zh) 2021-03-12
PL3188755T3 (pl) 2021-01-25
HUE053284T2 (hu) 2021-06-28
JP2022031791A (ja) 2022-02-22
LT3188755T (lt) 2020-12-28
JP2017526366A (ja) 2017-09-14
SMT202000589T1 (it) 2020-11-10
CN107074968A (zh) 2017-08-18
US10189877B2 (en) 2019-01-29
EP3188755B1 (en) 2020-08-05
MY201688A (en) 2024-03-13
MX2017002621A (es) 2017-07-28
MX2021006543A (es) 2021-10-13
US20170240601A1 (en) 2017-08-24
EP3188755A1 (en) 2017-07-12
PT3188755T (pt) 2020-09-29

Similar Documents

Publication Publication Date Title
Tripathi et al. Recent developments in recombinant protein–based dengue vaccines
US11926648B2 (en) Neutralising antibody against dengue for use in a method of prevention and/or treatment of Zika infection
Fahimi et al. Dengue viruses and promising envelope protein domain III-based vaccines
JP6655623B2 (ja) 新規多価ナノ粒子に基づくワクチン
Arora et al. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice
Arora et al. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
CA2988499A1 (en) Anti-dengue vaccines and antibodies
CN107847575B (zh) 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物
JP7333373B2 (ja) ワクチン
US11179460B2 (en) Virus-like particles comprising zika antigen
Tarr et al. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies
JP7068284B2 (ja) アセンブルした糖タンパク質
WO2015019253A2 (en) Anti-dengue virus genetic vaccine based on the envelope protein ectodomains
WO2008152652A2 (en) A dengue envelope domain iii-based tetravalent protein vaccine
KR101966841B1 (ko) 지카바이러스 e 단백질 유래의 재조합 항원 및 이의 용도
WO2020123759A1 (en) Subunit vaccine constructs for flaviviruses
HK40032428A (en) Vaccine
TWI787622B (zh) 登革次單位疫苗組成物
US20220372079A1 (en) Resurfaced dengue virus and ziki virus glycoprotein e diii variants and uses thereof
US10772949B2 (en) Dengue virus glycoprotein E DIII variants and uses thereof
Ximba Investigation of particulate HIV-1 Env vaccine candidates using Zera® and SpyTag/SpyCatcher technologies
Panapitakkul Stimulation of immune response in mice using the plant-produced SARS-CoV-2 S1 subunit protein linked to the fc region
WO2025146159A1 (zh) 针对寨卡/登革病毒的重组抗原、其疫苗组合物及其应用
Chao et al. A dengue monovalent vaccine with novel structure provides cross-protection against four serotypes of dengue virus
WO2014064707A1 (en) Pichia pastoris -expressed dengue virus like particles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190625

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200204

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200615

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20200616

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200616

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210323

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210810

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210921

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20211026

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20211026

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211124

R150 Certificate of patent or registration of utility model

Ref document number: 6983653

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250